Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CEO Sells 3,661 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 3,661 shares of the stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $76.37, for a total value of $279,590.57. Following the transaction, the chief executive officer now owns 62,897 shares of the company’s stock, valued at $4,803,443.89. This represents a 5.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Katherine Stueland also recently made the following trade(s):

• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total transaction of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $143,456.40.

GeneDx Trading Up 2.6 %

Shares of NASDAQ WGS traded up $1.89 during midday trading on Wednesday, hitting $73.83. The company’s stock had a trading volume of 256,611 shares, compared to its average volume of 455,360. The business’s 50 day moving average is $68.64 and its two-hundred day moving average is $44.59. GeneDx Holdings Corp. has a 12-month low of $1.58 and a 12-month high of $89.11. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. The firm has a market cap of $2.03 billion, a P/E ratio of -23.13 and a beta of 2.04.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.25. The business had revenue of $76.90 million during the quarter, compared to the consensus estimate of $64.98 million. GeneDx had a negative return on equity of 13.35% and a negative net margin of 31.25%. The business’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same period last year, the company earned ($0.82) earnings per share. As a group, equities research analysts expect that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Institutional Trading of GeneDx

A number of large investors have recently modified their holdings of the company. Acadian Asset Management LLC purchased a new position in GeneDx during the 2nd quarter worth $34,000. nVerses Capital LLC bought a new position in shares of GeneDx during the 2nd quarter worth $50,000. CWM LLC purchased a new position in shares of GeneDx during the third quarter valued at $89,000. SG Americas Securities LLC bought a new stake in shares of GeneDx in the third quarter valued at about $198,000. Finally, Point72 DIFC Ltd purchased a new stake in GeneDx in the third quarter worth about $220,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on WGS. The Goldman Sachs Group boosted their price objective on GeneDx from $54.00 to $70.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Wells Fargo & Company increased their price target on GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Finally, Craig Hallum lifted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $59.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.